JP2015511245A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511245A5
JP2015511245A5 JP2014558849A JP2014558849A JP2015511245A5 JP 2015511245 A5 JP2015511245 A5 JP 2015511245A5 JP 2014558849 A JP2014558849 A JP 2014558849A JP 2014558849 A JP2014558849 A JP 2014558849A JP 2015511245 A5 JP2015511245 A5 JP 2015511245A5
Authority
JP
Japan
Prior art keywords
amino
alkyl
phenyl
pyrido
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511245A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/027265 external-priority patent/WO2013126656A1/en
Publication of JP2015511245A publication Critical patent/JP2015511245A/ja
Publication of JP2015511245A5 publication Critical patent/JP2015511245A5/ja
Pending legal-status Critical Current

Links

JP2014558849A 2012-02-23 2013-02-22 ピリドピリミジノン系キナーゼ阻害薬 Pending JP2015511245A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602163P 2012-02-23 2012-02-23
US61/602,163 2012-02-23
PCT/US2013/027265 WO2013126656A1 (en) 2012-02-23 2013-02-22 Pyridopyrimidinone inhibitors of kinases

Publications (2)

Publication Number Publication Date
JP2015511245A JP2015511245A (ja) 2015-04-16
JP2015511245A5 true JP2015511245A5 (enExample) 2016-06-30

Family

ID=47757712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558849A Pending JP2015511245A (ja) 2012-02-23 2013-02-22 ピリドピリミジノン系キナーゼ阻害薬

Country Status (8)

Country Link
US (1) US9718821B2 (enExample)
EP (1) EP2817308B1 (enExample)
JP (1) JP2015511245A (enExample)
CN (1) CN104271576A (enExample)
CA (1) CA2864142A1 (enExample)
ES (1) ES2606640T3 (enExample)
MX (1) MX2014010176A (enExample)
WO (1) WO2013126656A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
US10233195B2 (en) * 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
CN106795154B (zh) * 2014-09-02 2019-07-05 皮埃尔法布雷医药公司 用于治疗癌症的异喹啉酮衍生物
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
BR112019002610A2 (pt) * 2016-08-15 2019-07-02 Pfizer piridopirimidinonas inibidoras de cdk2/4/6
ES2902050T3 (es) 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3652174A4 (en) * 2017-07-13 2021-06-30 Syros Pharmaceuticals, Inc. TAM KINASE INHIBITORS
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019074981A1 (en) 2017-10-09 2019-04-18 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AND USES THEREOF
PT3712150T (pt) 2017-11-01 2024-08-22 Wuxi Biocity Biopharmaceutics Co Ltd Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Wee1阻害剤としてのピリミドピラゾロン類誘導体及びその使用
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
JP2022528047A (ja) 2019-03-22 2022-06-08 ショウヤオ ホールディングス(ベイジン) カンパニー, リミテッド Wee1阻害剤、その製造および用途
WO2020210375A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US12291536B2 (en) 2019-04-30 2025-05-06 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of Wee1 inhibitor compound and use thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
KR20220159457A (ko) * 2020-03-27 2022-12-02 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
EP4332104A4 (en) 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
KR20240044409A (ko) * 2021-06-04 2024-04-04 아프레아 테라퓨틱스, 인크. Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
IL315441A (en) 2022-03-07 2024-11-01 Debiopharm Int Sa Treatment methods for small cell lung cancer
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
IL326854A (en) 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
WO2025133381A2 (en) 2023-12-22 2025-06-26 Debiopharm International S.A. Methods of treating solid tumors
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
EE200200506A (et) * 2000-03-06 2004-02-16 Warner-Lambert Company 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
DE602005002562T2 (de) * 2004-05-04 2008-01-31 Warner-Lambert Company Llc Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
AU2007211684A1 (en) * 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7H-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US8383635B2 (en) 2008-08-12 2013-02-26 Glaxosmithkline Llc Chemical compounds
EA201100879A1 (ru) * 2008-12-01 2012-01-30 Мерк Патент Гмбх Производные пиридопиримидина в качестве ингибиторов аутотаксина
US8575179B2 (en) * 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
MX2012004846A (es) * 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
WO2014023385A1 (en) * 2012-08-07 2014-02-13 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
EP2945632B1 (en) Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders
ES2271221T3 (es) Derivados imidazo-pirimidina como ligandos para receptores gaba.
JP2014506929A5 (enExample)
EP3883576B1 (en) Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
HRP20120105T1 (hr) Aminoheterociklički spojevi
JP2013519707A5 (enExample)
JP2016538316A5 (enExample)
ME02202B (me) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
AU2021370660A1 (en) Heterocyclic spiro compounds and methods of use
BRPI1012159A2 (pt) derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase.
JP2011500774A5 (enExample)
WO2015171527A1 (en) Pyrazolopyridine pyrazolopyrimidine and related compounds
JP2017531039A5 (enExample)
RU2017106742A (ru) Комбинированная терапия для лечения парамиксовируса
CA2682665A1 (en) Triazinone and diazinone derivatives useful as hsp90 inhibitors
RU2012139830A (ru) Производные пиразолопиперидина в качестве ингибиторов nadph - оксидазы
JP2016537384A5 (enExample)
JP2021512954A5 (enExample)
CA3050567A1 (en) Substituted dihydroimidazopyridinediones as mknk1 and mknk2 inhibitors
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
JP2017513887A5 (enExample)
JP2023078418A5 (enExample)
JP2013518823A5 (enExample)
JP2016517877A5 (enExample)